-
Become a Global Leader in Paediatric and Women’s Health
We are patient-centered, addressing the unmet medical needs in six therapeutic fields...
RESEARCH AND DEVELOPMENT
Sustaining Innovation...
-
70+
Marketed Products(*pharmaceuticals, diagnostic devices, and medical nutrition products, etc. )
-
26+
Clinical Pipeline
-
16.5%
R&D investment as a percentage of sales revenue in 2023
To challenge, to create, to push the boundaries of what is possible...
Latest News
-
2024-11-20
Chinese Monoclonal Anti-IL-1β Breakthrough: Acute Gout Arthritis Treatment Impresses at ACR 2024Learn More
-
2024-11-11
World ADC San Diego 2024: GenSci showcases two innovative pipeline programsLearn More
-
2024-11-07
Welcome to Visit Us at MEDICA 2024Learn More
-
2024-10-25
GenSci' s Inaugural R&D Day 2024: Innovation in Gene, Science in Actionsuccessfully concluded on October 17, 2024
Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More
-
2024-06-28
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® ApprovedA further step towards GenSci's vision of becoming a global leader in Pediatric and Women's Health
Learn More
-
2024-06-19
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia®Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia® in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.
Learn More
-
2024-06-05
Visit GenSci at CPhI China 2024At Booth W4E59, See you there!
Learn More
-
2024-05-26
NMPA Approves Genakumab Injection for Clinical Trial Commencementwhich marks the initiation of bioequivalence studies for the new formulation of Genakumab Injection
Learn More
-
2024-05-17
Jintrolong® PEG-SOMATROPIN from GenSci highlighted at ECE 2024Jintrolong® PEG-SOMATROPIN was highlighted during the Growth Hormone Research Society (GRS) symposium at the largest endocrine event in Europe
Learn More
-
2024-04-11
R&D Progress: NMPA Approves Genakumab to the MarketMajor R&D Progress
Learn More
-
2023-12-22
GenSci Launches Global Innovation Hub in ShanghaiThe Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges
Learn More